Safety of bazedoxifene in a randomized, double-blind, placebo- and active-controlled phase 3 study of postmenopausal women with osteoporosis

BACKGROUND: We report the safety findings from a 3-year phase 3 study (NCT00205777) of bazedoxifene, a novel selective estrogen receptor modulator under development for the prevention and treatment of postmenopausal osteoporosis. METHODS: Healthy postmenopausal osteoporotic women (N = 7,492; mean ag...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Christiansen, Claus, Chesnut, Charles H, Adachi, Jonathan D, Brown, Jacques P, Fernandes, César E, Kung, Annie WC, Palacios, Santiago, Levine, Amy B, Chines, Arkadi A, Constantine, Ginger D
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BioMed Central 2010
Konular:
Research Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC2908075/
https://ncbi.nlm.nih.gov/pubmed/20569451
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2474-11-130
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller